Andra Ap Fonden Seagen Inc. Transaction History

Andra Ap Fonden

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 09, 2023	BUY	$191.51 - $216.16 $727,738 - $821,408	3,800 Added 7.52%	54,300 $11.5 Million
Q2 2023 Aug 09, 2023	BUY	$187.64 - $206.25 $394,044 - $433,125	2,100 Added 4.34%	50,500 $9.72 Million
Q1 2023 May 12, 2023	SELL	$127.59 - $203.08 $2.16 Million - $3.43 Million	-16,900 Reduced 25.88%	48,400 $9.8 Million
Q4 2022 Feb 13, 2023	BUY	$117.37 - $139.17 $1.06 Million - $1.25 Million	9,000 Added 15.99%	65,300 $8.39 Million
Q3 2022 Nov 14, 2022	BUY	$135.27 - $180.11 $1.6 Million - $2.13 Million	11,800 Added 26.52%	56,300 $7.7 Million

Q2 2022 Aug 15, 2022	SELL	$108.81 - $179.33 $2.73 Million - $4.5 Million	-25,100 Reduced 36.06%	44,500 $7.87 Million
Q4 2021 Feb 15, 2022	SELL	$142.57 - $190.86 $869,677 - $1.16 Million	-6,100 Reduced 8.06%	69,600 $10.8 Million
Q3 2021 Nov 12, 2021	BUY	$142.45 - $169.82 $555,555 - $662,298	3,900 Added 5.43%	75,700 $12.9 Million
Q2 2021 Aug 16, 2021	BUY	$135.08 - $161.1 $5.69 Million - $6.78 Million	42,100 Added 141.75%	71,800 $11.3 Million
Q1 2021 May 17, 2021	SELL	$137.51 - $190.8 $1.32 Million - $1.83 Million	-9,600 Reduced 24.43%	29,700 $4.12 Million
Q4 2020 Feb 12, 2021	BUY	$164.63 - $211.93 $6.47 Million - $8.33 Million	39,300 New	39,300 $6.88 Million

1.26M

23K

55.2K

Ticker SGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,664,992
Description
Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment ...

Get notified when there are updates to the investment portfolio of Andra Ap Fonden, based on Form 13F filings with the SEC.

Stay updated on Andra Ap Fonden with notifications on news.